CoChat

Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology

Shah, Rashmi R. · 2019 · Drug Safety

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat. These agents are associated with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects. Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias. In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large number of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesised and are currently under clinical development. Preliminary evidence from early studies suggests that they may be effective in non-haematological cancers as well when used in combination with other therapeutic modalities, but that they too appear to be associated with the above class-related adverse effects. As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications wi…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40264-018-0773-9

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 69 references

Cited by

See all 202

Metadata

Authors
Shah, R. R.
Corresponding author
Shah, Rashmi R.
Venue
Drug Safety
Published
2019-01-16
Volume
42
Issue
2
Pages
235-245
ISSN
  • 0114-5916 (ISSN-L)
  • 1179-1942
OpenAlex
W2910383661
Cited by
197
References
69
Citations by year
2026: 24 · 2025: 46 · 2024: 26 · 2023: 25 · 2022: 25 · 2021: 24 · 2020: 19 · 2019: 7
FWCI
1.72
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Drug Safety (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
histone deacetylase inhibitors, tolerability, adverse drug reactions, myelosuppression, diarrhea, cardiotoxicity, QTc prolongation, atrial fibrillation, ventricular tachyarrhythmia, belinostat, chidamide, panobinostat, romidepsin, vorinostat, HDAC isoform selectivity, solid tumors, hematologic malignancies, T-cell lymphoma, multiple myeloma, combination therapy
MeSH terms
Animals, Antineoplastic Agents, Gastrointestinal Diseases, Histone Deacetylases, Humans, Hydroxamic Acids, Neoplasms, Sulfonamides, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. https://app.cochat.ai/papers/10.1007/s40264-018-0773-9
The paper
Shah, R. R. (2019). Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. Drug Safety. https://doi.org/10.1007/s40264-018-0773-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.